On May 25, 2023 Rutgers Cancer Institute of New Jersey and RWJBarnabas Health reported that data from SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL), and two abstracts from the neoadjuvant I-SPY 2 trial evaluating oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer, have been selected as late-breaking presentations at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held both in person in Chicago and online from June 2-6 (Press release, Rutgers Cancer Institute of New Jersey, MAY 25, 2023, View Source [SID1234632103]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are thrilled to have physician-scientists from our health system participate in two innovative clinical trials selected for three late-breaking presentations at this year’s ASCO (Free ASCO Whitepaper) annual meeting, reinforcing our commitment to push the boundaries of science, provide patients with cutting-edge treatment options, and transform the way cancer is treated," said Steven K. Libutti, MD, FACS, Director, Rutgers Cancer Institute of New Jersey and Senior Vice President, Oncology Services, RWJBarnabas Health. "As New Jersey’s only NCI-Designated Comprehensive Cancer Center, we strive to offer our patients comprehensive cancer care, including access to novel therapeutic advances and game-changing clinical trials that have the potential to save, extend and improve the quality of patients’ lives, and reshape the future of cancer management."
A total of 33 presentations and 9 publications have been accepted, highlighting research advances in several types of cancer, including lymphoma, pediatric, colorectal and breast cancer.
Highlights of additional accepted abstracts include the following:
Initial findings of the phase II study of biweekly TAS-102, irinotecan and bevacizumab in pre-treated metastatic colorectal cancer (mCRC), found that TAS-102 with irinotecan plus bevacizumab is an effective second-line therapy for patients with mCRC.
Findings from a cross-sectional, retrospective analysis that aimed to determine the association of receipt of treatment summaries, follow-up care instructions (including where to obtain "routine cancer check-ups"), and type of doctor providing survivorship care on breast cancer screening (BCS) and cervical cancer screening (CCS) in female cancer survivors. The analysis demonstrated that follow-up instructions, which are part of the survivorship plan, have the greatest association with BCS and CCS among cancer survivors, but despite this, about 25% of BCS and CCS-eligible cancer survivors did not receive them.
Results from a phase Ib/II clinical trial evaluating the preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors, which demonstrated that tinengotinib monotherapy was well-tolerated and the pharmacokinetics results may support dose recommendation for subsequent trials. Additionally, researchers observed encouraging anticancer activity of tinengotinib monotherapy in patients with heavily pre-treated solid tumors, including PC, HR+/HER2- BC, TNBC and CCA.
The full list of presentations at the 2023 ASCO (Free ASCO Whitepaper) Annual Meeting follows:
Oral Presentations
Abstract No.
Title
Presentation
Date/Time
Location
Abstract 8006
LINKER-MM1 study:
Linvoseltamab (REGN5458) in
patients with relapsed/refractory
multiple myeloma.
Saturday, June 3, 2023,
3:15 p.m. CDT
Hall D2 & Live Stream
Abstract 9501
Significant durable response with
fianlimab (anti-LAG-3) and
cemiplimab (anti-PD-1) in advanced
melanoma: Post adjuvant PD-1
analysis.
Monday, June 5, 2023,
3:00 p.m. CDT
Hall D1 & Live Stream
Abstract 1004
A phase 2 study of HER3-DXd in
patients (pts) with metastatic breast
cancer (MBC).
Monday, June 5, 2023,
12:42 p.m. CDT
Hall B1 & Live Stream
Abstract 10008
Phase 2 study of larotrectinib in
children with newly diagnosed
infantile fibrosarcoma (IFS):
Children’s Oncology Group (COG)
ADVL1823 cohort A.
Sunday, June 4, 2023,
12:09 p.m. CDT
S100a & Live Stream
Poster Presentations
Abstract No.
Title
Presentation
Date/Time
Location
Abstract
LBA612
Oral paclitaxel and dostarlimab with
or without trastuzumab in early-
stage, high-risk breast cancer:
Results from the neoadjuvant I SPY
2 TRIAL.
Sunday, June 4, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract
TPS3625
Phase II/III study of circulating
tumor DNA as a predictive
biomarker in adjuvant chemotherapy
in patients with stage II colon
cancer: NRG-GI005 (COBRA).
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract
TPS5103
SWOG S1823/CCTG GCC1:
Translational observational
investigational study of the liquid
biomarker microRNA 371a-3p in
newly diagnosed germ cell
tumours—Real-world trial design,
rapid accrual, and robust secondary
use of data opportunities.
Saturday, June 3, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract
TPS5109
HB-300, a novel arenavirus-based
cancer immunotherapy in patients
with metastatic castration-resistant
prostate cancer.
Saturday, June 3, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract
TPS5110
A phase 1/2 study of combination
olaparib and radium-223 in men
with metastatic castration-resistant
prostate cancer with bone metastases
(COMRADE): A trial in progress.
Saturday, June 3, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract
TPS9594
A phase 2/3 trial in progress on
tebentafusp as monotherapy and in
combination with pembrolizumab in
HLA-A*02:01+ patients with
previously treated advanced non-
uveal melanoma (TEBE-AM).
Saturday, June 3, 2023,
1:15 – 4:15 p.m. CDT
Hall A & On Demand
Abstract 532
A multicenter phase II study of
vaccines to prevent recurrence in
patients with HER-2–positive breast
cancer.
Sunday, June 4, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 2561
Clinical outcomes of immune
checkpoint inhibitor treatment in
patients with classic cold tumors
identified to have a high tumor
mutational burden via ctDNA.
Saturday, June 3, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 3085
Characterization of MCL-1 in
patients with colorectal cancer
(CRC): Expression, molecular
profiles, and outcomes.
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 3531
Chemotherapeutic sensitivity in
colorectal cancer expressing low
RNA of wild type homologous
recombination genes.
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 3590
Phase II study of biweekly TAS-
102, irinotecan and bevacizumab in
pre-treated metastatic colorectal
cancer (TABAsCO).
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 3622
Molecular profiling and
characterization of the tumor
immune microenvironment (TME)
in appendiceal carcinoma (AC).
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4108
Comprehensive profiling of clock
genes expression in hepatocellular
carcinoma (HCC).
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4144
Correlation of comprehensive
molecular mapping of pancreatic
ductal adenocarcinoma with XPO1
mRNA expression levels to potential
clinical targets.
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4145
Clinical genomic implications of
transcriptional subtypes in
pancreatic cancer.
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4150
KRAS G12C-mutated pancreatic
cancer: Clinical outcomes based on
chemotherapeutic regimen.
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4151
Molecular and clinical correlates of
DSCR1 expression in pancreatic
cancer (PDAC).
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 4167
The five periampullary cancers: Not
just different siblings but different
families—An international
multicenter cohort study.
Monday, June 5, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 9548
A phase 1 study of fianlimab (anti-
LAG-3) in combination with
cemiplimab (anti-PD-1) in patients
with advanced melanoma: Poor-
prognosis subgroup analysis.
Saturday, June 3, 2023,
1:15 – 4:15 p.m. CDT
Hall A & On Demand
Abstract 10628
Learned lessons from a US-wide
outreach program to broaden
enrollment to the PROMISE
Registry, a prostate cancer genetic
registry.
Saturday, June 3, 2023,
1:15 – 4:15 p.m. CDT
Hall A & On Demand
Abstract 11018
Characterizing imposter syndrome
among oncologists on social media.
Sunday, June 4, 2023,
8:00 – 11:00 a.m. CDT
Hall A & On Demand
Abstract 12075
Survivorship care and breast and
cervical cancer screening.
Monday, June 5, 2023,
1:15 – 4:15 p.m. CDT
Hall A & On Demand
Poster Discussion Session
Abstract 2519
A phase I/II trial investigating safety
and efficacy of autologous TAC01-
HER2 in relapsed or refractory solid
tumors.
Saturday, June 3, 2023,
3:00 – 4:30 p.m. CDT
S100bc & On Demand
Abstract 3019
Preliminary safety and efficacy of
tinengotinib tablets as monotherapy
and combination therapy in
advanced solid tumors: A phase Ib/II
clinical trial.
Saturday, June 3, 2023,
2:11 p.m. CDT
S100bc & On Demand
Abstract 4020
Not all treated KRAS-mutant
pancreatic adenocarcinomas are
equal: KRAS G12D and survival
outcome.
Monday, June 5, 2023,
11:30 – 1:00 p.m. CDT
Hall D2 & Live Stream
Abstract 7515
Response-adapted therapy (tx) with
nivolumab plus brentuximab vedotin
(nivo + BV) without autologous
hematopoietic cell transplantation
(auto-HCT) in children, adolescents,
and young adults (CAYA) with low-
risk relapsed/refractory (R/R) classic
Hodgkin lymphoma (cHL):
CheckMate 744.
Monday, June 5, 2023,
1:49 p.m. CDT
E450 & On Demand
Abstract Discussion 4
Aging in Survivors of Pediatric
Cancer
Monday, June 5, 2023,
5:36 p.m. CDT
S504 & On Demand
Abstract LBA520
Oral paclitaxel, carboplatin, and
dostarlimab (OPE/Cb/D) without
and with trastuzumab in early-stage,
high-risk breast cancer: Results from
the neoadjuvant I-SPY 2 TRIAL.
Sunday, June 4, 2023,
5:04 p.m. CDT
Hall B1 & Live Stream
Plenary Session
Abstract LBA4
SWOG S1826, a randomized study
of nivolumab(N)-AVD versus
brentuximab vedotin (BV)-AVD in
advanced stage (AS) classic
Hodgkin lymphoma (HL).
Sunday, June 4, 2023,
2:53 p.m. CDT
Hall B1 & Live Stream
Publication Only
Session title
Presentation title
Presentation
Date/Time
Location
Abstract e16073
Preoperative pembrolizumab for
MSI high, EBV positive or PD-L1
positive locally advanced gastric
cancer followed by surgery and
adjuvant chemoradiation with
pembrolizumab: Interim results of a
phase 2 multi-center trial.
N/A
N/A
Abstract e18723
Assessment of how differences in
efficacy and toxicity change
healthcare professionals’ views on
presentation of treatment options.
N/A
N/A
Abstract e15087
Safety and feasibility of the addition
of a radiosensitizing methionine-
restricted diet to radiation therapy.
N/A
N/A
Abstract e17618
Comparing sentinel
lymphadenectomy and complete
lymphadenectomy among obese
patients (BMI >30) undergoing
minimally invasive hysterectomy for
early-stage endometrial cancer: An
ACS-NSQIP database study.
N/A
N/A
Abstract e18605
Immediate inpatient toxicities
associated with CAR T-cell therapy:
Real world data from a national
inpatient sample.
N/A
N/A
Abstract e24088
Barriers to offering female fertility
preservation to pediatric and young
adult oncology patients: A national
survey of pediatric hematology
oncology providers in the United
States and Canada.
N/A
N/A
Abstract e12523
ctDNA detection before and during
systemic therapy for inflammatory
breast cancer.
N/A
N/A
Abstract e16079
Outcomes of Helicobacter pylori
(HP) infection in esophageal cancer
(EC): A 5-year nationwide analysis.
N/A
N/A
Abstract e19015
Pevonedistat plus belinostat in
relapsed/refractory acute myeloid
leukemia or myelodysplastic
syndrome: A phase I multicenter
study.
N/A
N/A